NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/13/2025
Back to search
Official data from USPTO
EPIXIENNE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
05/13/2025
Trademark type
Word
Nice classes
5
Filing date
08/12/2022
Registration date
05/13/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/13/2025
Last transaction
05/13/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Leverkusen, DE
Examiner
COLLIER, DAVID
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
B. A. (pessoa física)
Representatives
Phillip Barengolts Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for humans for treatment of gynecological pain diseases and inflammatory diseasesdisordersdeficiencies; pharmaceutical preparations for humans for treatment of cardiological pain and inflammatory diseasesdisordersdeficiencies; pharmaceutical preparations for treatment of cysticpaininflammatory diseases of the kidney; pharmaceutical preparations for humans for treatment of pain and inflammation caused by hormone related disorderscancergenetic deficiencies; none of the foregoing including hygiene products or preparations for treating skin disorders
Publications
History of USPTO decisions and trademark events.
35 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/13/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/25/2025
PUBO
PUBLISHED FOR OPPOSITION
03/25/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/19/2025
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/03/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/11/2025
GNRT
NON-FINAL ACTION E-MAILED
02/11/2025
CNRT
NON-FINAL ACTION WRITTEN
02/11/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/03/2025
ALIE
ASSIGNED TO LIE
01/30/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/27/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/27/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/17/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/17/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/17/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
08/26/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
02/28/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/31/2023
GNSL
LETTER OF SUSPENSION E-MAILED
08/31/2023
CNSL
SUSPENSION LETTER WRITTEN
08/31/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/29/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/29/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2023
GNRT
NON-FINAL ACTION E-MAILED
06/02/2023
CNRT
NON-FINAL ACTION WRITTEN
06/02/2023
DOCK
ASSIGNED TO EXAMINER
06/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/31/2022
NWAP
NEW APPLICATION ENTERED
08/16/2022
Continuous trademark protection
Get notified about every new filing that threatens EPIXIENNE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.